






QUIBIM algorithms, viewer and platform get CE Mark certification

Valencia, Spain – 11th January 2019. QUIBIM Precision® image analysis platform has received CE Mark certification as class IIa Medical Device, including the imaging biomarker analysis algorithms, the zero footprint DICOM viewer and the platform hosting these components and medical imaging data. With this milestone the products are now ready for commercial deployment in European hospitals and diagnostic imaging centres.

The platform, which includes not only quantitative image analysis but also structured reporting capabilities, can be seamlessly integrated into the radiology workflow adding value to the specialists. In addition to the platform, this certification includes 15 algorithms grouped in the 5 main pillars of QUIBIM:

 <p>Longitudinal white matter lesions</p> <p>Description Application designed for a new lesion detection and determination of volume changes of white matter lesions between 2 different time points. Global brain volumetry is also included.</p> <p>Application Neurological diseases and disorders, Longitudinal follow-up.</p> <p>Neuro White matter lesions</p> <p>Not for clinical use</p>	 <p>Liver Fat and Iron concentration</p> <p>Description Application designed for liver fat and iron quantification in diffuse diseases.</p> <p>Application Steatohepatitis, Hemochromatosis, Inflammatory Activity.</p> <p>Liver Diffuse diseases</p> <p>510k pending</p>	 <p>Perfusion - Pharmacokinetics modeling</p> <p>Description Application designed for a tissue perfusion analysis based on a bicompartmental pharmacokinetic model.</p> <p>Application Tumor lesions, Tissue vascularization.</p> <p>Oncology Bicompartmental model Vascularization</p> <p>510k pending</p>	 <p>Lung emphysema</p> <p>Description Application designed for lung and emphysema volume measurements for each lung through an adaptative threshold method.</p> <p>Application Lung emphysema, COPD, Pulmonary hypertension, Fibrosis.</p> <p>Lung Emphysema Threshold</p> <p>Not for clinical use</p>	 <p>Femoral cartilage T1 mapping</p> <p>Description Application designed for femoral cartilage T1 extraction.</p> <p>Application Osteoarthritis, Cartilage morphology.</p> <p>Femoral Cartilage T1 Map</p> <p>Not for clinical use</p>
---	--	--	--	---

- **Oncology:** ADC Diffusion, IVIM Diffusion, Semiquantitative Perfusion, Pharmacokinetics Modeling, T1 mapping, T2 mapping.
- **Neurology:** White matter lesions detection, Brain atrophy modules.
- **Musculoskeletal:** 3D /2D Trabecular Bone Microarchitecture
- **Liver:** Liver fat and Iron quantification.
- **Lung:** Lung Emphysema and densities.



Also included in the CE Mark certification is the DataMiner, which is designed to provide advanced visual analytics of large databases of patients for population health management and scientific exploitation, and the DICOM web viewer that enables the user to visualize the images of a sequence, draw ROIs or apply filters.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 778064

QUIBIM algorithms, viewer and platform get CE Mark certification

"We are so proud of getting the ISO 13485:2016 and the CE certification by BSI, one of the most prestigious notified bodies. This allows QUIBIM to commercialize QUIBIM Precision® as a Medical Device in the European market, which is a major milestone for our company.", states **Ángel Alberich Bayarri, CEO & Co-founder of QUIBIM**. He adds, "Since its inception, QUIBIM has done extensive research and validation for its products together with European, American, Indian, and South American partners, ranging from top academic and research hospitals & diagnostic centres to the leading pharmaceutical companies and CRO's, sharing the results in publications in both national and international congresses. Now with the CE Mark approval, QUIBIM is excited to commercialize its efforts in Europe and the regions of the world where the CE Mark is accepted."

"QUIBIM is a company committed to improving diagnosis, which has a huge impact on patients quality of life. Therefore, quality is one of the aspects we pursue the most in our company, not only by certifying the quality of our product with the CE Mark but also at the organizational level. This is why we have established our Quality Management System based on and certified by the ISO 13485:2016, a standard related to the quality management system applicable to medical devices." pointed **Belén Fos Guarinos, Quality Assurance And Regulatory Affairs Manager** at QUIBIM.

About QUIBIM

QUIBIM is a company from Valencia (Spain) which applies artificial intelligence and advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology. QUIBIM Precision® is the image repository and analysis platform provided by the company and is increasingly being used by customers across hospitals, clinical trials, research projects, biobanks and educational institutions across the world. The company is member of the European Institute of Biomedical Imaging Research (EIBIR) and of the Avicenna Alliance and receives funding from the H2020 program of the European Commission.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 778064

More information at:

contact@quibim.com
www.quibim.com
+34 961 243 225